查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1553471

僵直性脊椎炎市場規模、佔有率、趨勢分析報告：按藥物類別、分銷管道、地區、細分市場預測，2024-2030 年

Ankylosing Spondylitis Market Size, Share & Trends Analysis Report By Drug Class (Non-steroidal Anti Inflammatory, TNF Inhibitors), By Distribution Channel (Hospital Pharmacy), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

僵直性脊椎炎市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球僵直性脊椎炎市場規模將達到91.2億美元，2024年至2030年複合年成長率為6.4%。

強大產品平臺的存在可能會加速市場成長。例如，UCB SA的研發線產品bimekizumab在2B期試驗中顯示出正面的結果，使其成為預測期內推向市場的潛在候選藥物。

製藥公司的目標是擴大標籤和專利範圍，以維持市場佔有率。 2017 年 10 月，強生服務公司的 AS 治療藥物Simponi獲得核准，用於治療活動性乾癬性關節炎(PsA) 或活動性僵直性脊椎炎(AS)。這些治療領域的進步預計將對市場成長產生積極影響。

此外，有利的報銷政策的存在也有望促進成長。例如，在加拿大（安大略省）公共藥物計劃中，諾華宣布報銷 Cosentyx 用於治療強直性強直。根據諾華公司發表的一篇論文，大約 20% 至 40% 的患者在使用抗 TNF 藥物後沒有獲得足夠的臨床改善。

僵直性脊椎炎市場報告亮點

  • TNF（腫瘤壞死因子）細分市場佔據主導地位，2023 年銷售佔有率為 59.4%。 TNF 抑制劑以腫瘤壞死因子為標靶來治療類風濕性關節炎等自體免疫疾病，預計將顯著成長。
  • 預計非類固醇消炎劑(NSAID) 市場在預測期內將以 8.8% 的複合年成長率成長。
  • 北美僵直性脊椎炎市場2023年佔最大銷售佔有率，達57.9%。
  • 主要企業正在採取產品開拓、併購和區域擴張等策略來增加市場佔有率。
  • 例如，2019年1月，三星Bioepis有限公司宣布與三生製藥建立策略夥伴關係，以擴大產品系列。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章全球僵直性脊椎炎市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 全球僵直性脊椎炎市場分析工具
    • 波特的分析
    • PESTEL分析

第4章全球僵直性脊椎炎市場：藥物類別估計與趨勢分析

  • 細分儀表板
  • 全球僵直性脊椎炎市場：藥物類別變化分析（百萬美元），2023-2030 年
  • 非類固醇消炎劑(NSAID)
  • 腫瘤壞死因子抑制劑
  • 其他藥物類別

第5章全球僵直性脊椎炎市場：通路估算及趨勢分析

  • 細分儀表板
  • 全球僵直性脊椎炎市場：分銷管道波動分析，百萬美元，2023-2030
  • 醫院藥房
  • 零售藥房
  • 其他

第6章全球僵直性脊椎炎市場：區域估計與趨勢分析

  • 全球僵直性脊椎炎市場佔有率（按地區），2023 年和 2030 年，百萬美元
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 科威特

第7章 競爭格局

  • 最新趨勢與影響分析：主要市場參與企業
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • AbbiVie, Inc
    • Amgen, Inc.
    • Pfizer, Inc.
    • UCB, Inc.
    • Novartis AG
    • Eli Lilly and Company
    • Johnson and Johnson Services, Inc.
    • Merck and Co., Inc.
簡介目錄
Product Code: GVR-4-68038-728-5

Ankylosing Spondylitis Market Growth & Trends:

The global ankylosing spondylitis market size is expected to reach USD 9.12 billion by 2030, registering a CAGR of 6.4% from 2024 to 2030, according to a new report by Grand View Research, Inc. Presence of a strong product pipeline is likely to accelerate market growth. For instance, the positive phase-2b results of UCB S.A. pipeline product, Bimekizumab, makes it a potential drug candidate to be launched in the market over the forecast period.

Pharmaceutical companies are aiming at label expansion and patent extension for maintaining their share in the market. In October 2017, Johnson & Johnson Services received approval for Simponi Aria for AS treatment for the treatment active psoriatic arthritis (PsA) or active ankylosing spondylitis (AS). Such advancements in therapy area are expected to have a positive effect on the market growth.

Furthermore, presence of favorable reimbursement policies is anticipated to propel the growth. For instance, in Canada (Ontario) under the province's public drug program, Novartis AG announced the reimbursement of Cosentyx for the treatment of ankylosing ankylosis. According to an article published by Novartis AG, approximately 20 to 40% of patients fail to achieve sufficient clinical improvement on anti-TNF drugs, which provides opportunities for companies to develop novel and effective drugs.

Ankylosing Spondylitis Market Report Highlights:

  • The TNF (Tumor Necrosis Factor) segment dominated the market and accounted for a revenue share of 59.4% in 2023. TNF inhibitors, which target tumor necrosis factors to manage autoimmune conditions such as rheumatoid arthritis, are anticipated to experience significant growth.
  • The Non-steroidal Anti-Inflammatory Drug (NSAID) market is expected to grow at a CAGR of 8.8% over the forecast years.
  • The North America ankylosing spondylitis market accounted for the largest revenue share of 57.9% in 2023
  • Key companies are adopting strategies, such as product development, M&A, and regional expansion, to increase their market share
  • For instance, in January 2019, Samsung Bioepis Co., Ltd. announced the strategic partnership with 3SBio Inc. to expand its product portfolio in China

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Global Ankylosing Spondylitis Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Global Ankylosing Spondylitis Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Global Ankylosing Spondylitis Market: Drug Class Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Ankylosing Spondylitis Market: Drug Class Movement Analysis, USD Million, 2023 & 2030
  • 4.3. Non-Steroidal Anti Inflammatory Drugs (NSAIDs)
    • 4.3.1. Non-Steroidal Anti-Inflammatory Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. TNF Inhibitors
    • 4.4.1. TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.2. Humira
      • 4.4.2.1. Humira Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.3. Simponi
      • 4.4.3.1. Simponi Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.4. Remicade
      • 4.4.4.1. Remicade Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.5. Enbrel
      • 4.4.5.1. Enbrel Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.6. Cimzia
      • 4.4.6.1. Cimzia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 4.4.7. Other TNF Inhibitors
      • 4.4.7.1. Other TNF Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Other Drug Classes
    • 4.5.1. Other Drug Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Global Ankylosing Spondylitis Market: Distribution Channel Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Ankylosing Spondylitis Market: Distribution Channel Movement Analysis, USD Million, 2023 & 2030
  • 5.3. Hospital Pharmacy
    • 5.3.1. Hospital pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Retail Pharmacy
    • 5.4.1. Retail pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Others
    • 5.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Global Ankylosing Spondylitis Market: Regional Estimates & Trend Analysis

  • 6.1. Global Ankylosing Spondylitis Market Share, By Region, 2023 & 2030, USD Million
  • 6.2. North America
    • 6.2.1. North America Global Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK
      • 6.3.2.1. UK Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. China
      • 6.4.2.1. China Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. Japan
      • 6.4.3.1. Japan Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. South Korea
      • 6.4.5.1. South Korea Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. Australia
      • 6.4.6.1. Australia Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. Saudi Arabia
      • 6.6.2.1. Saudi Arabia Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. UAE
      • 6.6.3.1. UAE Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. South Africa
      • 6.6.4.1. South Africa Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Ankylosing Spondylitis Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. AbbiVie, Inc
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Amgen, Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Pfizer, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. UCB, Inc.
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Novartis AG
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Eli Lilly and Company
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Johnson and Johnson Services, Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. Merck and Co., Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives